JW Shinyak Corporation Cash Flow Conversion Efficiency

Latest as of September 2025: 0.115x

JW Shinyak Corporation cash flow conversion efficiency. Based on the latest financial reports, JW Shinyak Corporation (067290) has a cash flow conversion efficiency ratio of 0.115x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.46 Billion ≈ $3.03 Million USD) by net assets (₩38.73 Billion ≈ $26.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of JW Shinyak Corporation (2007–2024)

Cash flow conversion efficiency of JW Shinyak Corporation from 2007 to 2024. This chart illustrates how JW Shinyak Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 067290 live share price for real-time trading data and today's change.

JW Shinyak Corporation Cash Flow Conversion Ratio Explained

JW Shinyak Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

JW Shinyak Corporation Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of JW Shinyak Corporation ranked by their cash flow conversion efficiency. Also see JW Shinyak Corporation stock valuation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
A SPAC II Acquisition Corp. Ordinary Shares
NASDAQ:ASCB
0.036x
Cube Entertainment Inc
KQ:182360
-0.108x
Computacenter PLC
LSE:CCC
-0.097x
Rani Therapeutics Holdings Inc
NASDAQ:RANI
-0.188x
Protech Mitra Perkasa Tbk PT
JK:OASA
-0.061x
Daewon Media Co. Ltd
KQ:048910
0.095x
G J Steel Public Company Limited
BK:GJS
0.051x
Space Shuttle Hi-Tech Co Ltd
TW:2440
-0.127x

Annual Cash Flow Conversion Efficiency for JW Shinyak Corporation (2007–2024)

The table below shows the annual cash flow conversion efficiency of JW Shinyak Corporation from 2007 to 2024. Review JW Shinyak Corporation free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩26.90 Billion
≈ $18.23 Million
₩8.44 Billion
≈ $5.72 Million
0.314x +101.71%
2023-12-31 ₩16.44 Billion
≈ $11.14 Million
₩2.56 Billion
≈ $1.73 Million
0.156x +22.16%
2022-12-31 ₩55.97 Billion
≈ $37.93 Million
₩7.13 Billion
≈ $4.83 Million
0.127x -9.16%
2021-12-31 ₩55.44 Billion
≈ $37.57 Million
₩7.77 Billion
≈ $5.27 Million
0.140x +93.40%
2020-12-31 ₩56.56 Billion
≈ $38.33 Million
₩4.10 Billion
≈ $2.78 Million
0.072x +11.25%
2019-12-31 ₩66.14 Billion
≈ $44.82 Million
₩4.31 Billion
≈ $2.92 Million
0.065x -70.53%
2018-12-31 ₩33.49 Billion
≈ $22.69 Million
₩7.40 Billion
≈ $5.02 Million
0.221x +426.23%
2017-12-31 ₩36.83 Billion
≈ $24.96 Million
₩-2.50 Billion
≈ $-1.69 Million
-0.068x -451.98%
2016-12-31 ₩38.60 Billion
≈ $26.16 Million
₩743.20 Million
≈ $503.66K
0.019x +3608.61%
2015-12-31 ₩40.23 Billion
≈ $27.26 Million
₩-22.08 Million
≈ $-14.96K
-0.001x +98.99%
2014-12-31 ₩42.46 Billion
≈ $28.77 Million
₩-2.31 Billion
≈ $-1.56 Million
-0.054x -246.92%
2011-12-31 ₩52.81 Billion
≈ $35.79 Million
₩1.95 Billion
≈ $1.32 Million
0.037x -65.66%
2007-12-31 ₩27.49 Billion
≈ $18.63 Million
₩2.96 Billion
≈ $2.01 Million
0.108x --

About JW Shinyak Corporation

KQ:067290 Korea Pharmaceuticals
Market Cap
$63.63 Million
₩93.90 Billion KRW
Market Cap Rank
#20794 Global
#1180 in Korea
Share Price
₩2260.00
Change (1 day)
+1.80%
52-Week Range
₩1254.00 - ₩3890.00
All Time High
₩10766.98
About

JW Shinyak Corporation, a pharmaceutical company, engages in the production and sale of medicines and medical supplies in South Korea. The company offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesi… Read more